WHAT IS GPPAD?
The Global Platform for the Prevention of Autoimmune Diabetes GPPAD was initiated in 2015. Its goal is to provide an international infrastructure that will enable type 1 diabetes primary prevention trials. These trials will be built around programs that identify infants with an elevated genetic predisposition for type 1 diabetes, and will aim to reduce the incidence of the beta-cell autoimmunity that precedes clinical diabetes in children.
Freder1k Study in Saxony: Early Detection of the Risk of Developing Type 1 Diabetes
The number of children developing type 1 diabetes is rising. Learn about the Freder1k study’s efforts to detect the risk of developing type 1 diabetes.
CLINICAL STUDY CENTERS
Central office: Institut für Diabetesforschung
Helmholtz Zentrum München
Ingolstädter Landstraße 1
Phone +49 - (0)89 - 3187 2896